Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

Immatics Biotechnologies lands €1.1bn deal with GSK

The companies’ strategic alliance aims to equip patients' own T cells with a natural T cell receptor that recognises antigens on solid tumours....

German and UK researchers cut time to sepsis diagnosis

In the Journal of Molecular Diagnostics, a research team led by Kai Sohn from Fraunhofer IGB (Stuttgart, Germany) describes the new real-time...

Experts discuss link between sepsis and Covid-19

At a virtual conference on sepsis and its relation to Covid-19 held at the University Hospital Charité in Berlin, Niels Riedemann, CEO of Inflarx NV,...

Royal DSM acquires Glycom A/S for €765m

The Dutch industry giant for nutrition, health and sustainable products paid €765m for Glycom A/S, which made €74m of sales in 2019, mainly from a...

Antabio SAS advances cystic fibrosis programme

Antabio said it will use the second tranche of a 2017 CARB-X grant to complete non-GLP studies on the company‘s Pseudomonas Elastase inhibitor (PEi)...

EU diagnostic labs prepared for Sars-CoV-2

According to a survey carried out by the European Centre for Disease Prevention and Control (ECDC) and published in Eurosurveillance, 38 of 47...

Merck and 4SC collaborate in immunooncology

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC...